CD40LG and myeloid sarcoma: To study in detail the role of IgM-PC as a prognosis biomarker, we analyzed the effect of the different treatments on the level of these immunoglobins, comparing the levels of IgM-PC before and after the treatment (IgMPC.a.t) in paired samples from MS patients (Table 2).